Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Current status of human papillomavirus vaccination

Brotherton, Julia M.L.a,b; Ogilvie, Gina S.c,d

doi: 10.1097/CCO.0000000000000211
GYNECOLOGIC CANCER: Edited by Martin Gore

Purpose of review In this article, we review the impact of the quadrivalent and bivalent prophylactic human papillomavirus (HPV) vaccines on HPV infection and disease, review alternative vaccine dosing schedules, the vaccination of men and the nine-valent HPV vaccine.

Recent findings HPV vaccines have had dramatic impacts on the prevalence of targeted HPV types (6,11,16 and 18), genital warts and precancerous cervical lesions. Population coverage would be facilitated by adopting two-dose schedules, with recent findings that two-dose schedules in young adolescents are as immunogenic as three doses in young adults. Extension of vaccination to men, particularly for men who have sex with men, could further reduce population prevalence of HPV and provide direct protection to men against genital warts and anal, penile and oropharyngeal cancers. The nine-valent HPV vaccine has demonstrated equivalent protection against the four types in the quadrivalent vaccine and high efficacy against the next five commonest causes of cervical cancer (HPV types 31,33,45,52 and 58). If cost-effective, it may extend the spectrum of protection against cervical cancer available through vaccination.

Summary HPV vaccination is an effective strategy for reducing the burden of HPV-related disease. New schedules, target populations and vaccines promise to expand this potential further.

aNational HPV Vaccination Program Register, East Melbourne

bSchool of Population and Global Health, University of Melbourne, Victoria, Australia

cSchool of Population and Public Health, University of British Columbia, Vancouver

dWomen's Health Research Institute, BC Women's Health Centre, Vancouver, British Columbia, Canada

Correspondence to A/Prof Julia M.L. Brotherton, National HPV Vaccination Program Register, PO Box 310, East Melbourne, VIC 8002, Australia. Tel: +61 3 9250 0377; e-mail:

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.